Use of erythropoietin in oncology;Uso dell'eritropoietina in oncologia

Tumori

Volumn 83, Issue 4 SUPPL. 2, 1997, Pages

  Rosso, Riccardo ^a   Del Mastro, Lucia ^a   Venturini, Marco ^a   Bergaglio, Marina ^a   Pasquetti, Wanda ^a   Garrone, Ornella ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

anemia; erythropoietin; review

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; ERYTHROPOIETIN; FLUOROURACIL;

ANEMIA; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HEMOGLOBIN DETERMINATION; HEMOSIDEROSIS; HUMAN; ONCOLOGY;

ANEMIA; ANTINEOPLASTIC AGENTS; ERYTHROPOIETIN; HUMANS; NEOPLASMS;

EID: 0030829735     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Abels RI. Recombinant human eythropoietin in the treatment of the anaemia of cancer. Acta Hematol 87 (suppl 1): 4-11; 1992.
2. Ardizzoni A., Venturini M., Crinò L., Sertoli M.R., Bruzzi P., Pennucci M.C., Mariani G.L., Garrone O., Bracarda S., Rosso R., Van Zandwijk N.: High dose-intensity chemotherapy, with accelerated cyclophosphamide-doxorubicin-etoposide and Granulocyte-Macrophafe Colocy Stimulating Factor, in the treatment of small cell lung cancer. Eur. J. Cancer, 29A: 687-692, 1993.
3. Ardizzoni A., Venturini M., Sertoli M.R., Giannessi P.G., Brema F., Danova M., Testore F., Mariani G.L., Pennucci M.C., Queirolo P., Bruzzi P., Lionetto R., Latini F., Rosso R.: Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancer. Br. J. Cancer, 69: 385-391, 1994.
4. Chao N.J., Schriber J.R., Long G.D., Negrin R.S., Catolico M., Brown W., Miller L.L., Blume KG.: A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with hodgkin's and non -hodgkin's lynphoma undergoing autologous bone marrow transplantation. Blood, 83: 2823-2828, 1994.
5. Cascinu S., Fedeli A., Del Ferro E., Luzi Fedeli S., Catalano G.: Recombinant human erythropoietin treatment in Cisplatin-associated anemia: a randomized, double-blind trial with placebo. J. Clin. Oncol., 12:1058-1062, 1994.
6. Case D.C., Bukowski R.M., Carey R.W., Fishkin E.H., Henry D.H., Jacobson R.J., Jones S.E., Keller A.M., Kugler J.W., Nichols C.R., Salmon S.E., Silver R.T., Storniolo A.M., Wampler G.L., Dooley C.M., Larholt K.M., Nelson R.A., Abels R.I.: Recombinant human erythropoietin therapy for anemic patients on combination chemotherapy. J. Natl. Cancer Inst., 85:801-806, 1993.
7. Cazzola M., Messinger D., Battistel V., Bron D., Cimino R., Enller-Ziegler L., Essers U., Greil R., Grossi A., Jager G., LeMevel A., Najman A., Silingardi V., Spriano M., Achiel van Hof, Ehmer B.: Recombinant human erythropoietin in the anemia associated with multiple mieloma or non-hodgking's linphoma: dose finding and identification of predictors of response. Blood, 86: 4446-4453. 1995.
8. de Campos E., Radford J., Steward W., Milroy R., Dougal M., Swindell R., Testa N., Thatcher N.: Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for Small-Cell Lung Cancer. J. Clin. Oncol., 13:1623-1631, 1995.
9. Del Mastro L., Garrone O., Sertoli M.R., Canavese G., Catturich A., Guenzi M., Rosso R., Venturini M.: A pilot study of accelerated cyclophosphamide, epirubicin and 5-fluorouracil plus granulocyte colony stimulating factor as adjuvant therapy in early breast cancer. Eu.r J. Cancer, 30A: 606-610, 1994.
10. Del Mastro L., Venturini M., Lionetto R., Garrone O., Melioli G., Pasquetti W., Sertoli M.R., Bertelli G., Canavese G., Costantini M., Rosso R.: Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy -induced anemia. J. Clin. Oncol., 15: 2715-2721, 1997.
11. Eschbach J.W., Abdulhadi M.H., Browne J.K., Delano B.G., Downing M.R., Egrie J.C., Evans R.W., Friedman E.A., Graber S.E., Haley N.R., Korbet S., Krantz S.B., Lundin A.P., Nissenson A.R., Ogden D.A., Paganini E.P., Rader B., Rutsky E.A., Stivelman J., Stone W.J., Teschan P., Van Stone J.C., Van Wyck D.B., Zuckerman K., Adamson JW.: Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter trial. Ann. Int. Med., 111: 992-1000, 1989.
12. Focan C., Andrien J.M., Closon M.Th., Dicato M., Driesschaert P., Focan-Henrard D., Lemaire M., Lobelle J.P., Longree L., Ries F.: Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: a prospective randomized trial. J. Clin. Oncol., 11: 1253-1263, 1993.
13. Glaspy J., Bukowski R., Steinberg D., Taylor C., Tchekmedyian S., Vadhan-Rai S., for the Pocrit Study Group. Impact of therapy with epoetin alfa on clinical outcomes with nonmyeloid malignancies during cancer oncology practice. J. Clin. Oncol., 15: 1218-1234, 1997.
14. Henry D.H., Abels R.I.: Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies. Sem. Oncol., 21:21-28, 1994.
15. Henry D.H., Beall G.N., Benson C.A., Carey J., Cone L.A., Eron L.J., Fiala M., Fischl M.A., Gabin S.J., Gottlieb M.S., Galpin J.E., Groopman J.E., Hooton T.M., Jemsek J.G., Levine R.L., Miles S.A., Rinehart J.J., Rios A., Robbins W.J., Ruckdeschel J.C., Smith J.A., Spruance S.L., Starrett B., Toney J., Zalusky R., Abels R.I., Bryant E.C., Larholt K.M., Sampson A.R., Rudnick S.A.: Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials. Ann. Int. Med., 117: 739-748, 1992.
16. Henry D.H., Thatcher N.: Patient selection and predicting response to recombinant human erythropoietin in anemic cancer patients. Sem. Haematol., 33: 2-5, 1996.
17. Jacobs K., Shoemaker C., Rudersdorf R., Neill S.D., Kaufman R.J., Mufson A., Seehra J., Jones S.S., Hewick R., Fritsch E.F., Kawakita M., Shimizu T., Miyake T.: Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature, 313: 806-810, 1985.
18. Kaye S.B., Lewis C.R., Paul C.R., Duncan I.D., Gordon H.K., Kitchener H.C., Cruickshank, Atkinson R.J., Soukop M., Rankin E.M., Cassidy J., DAVIS J.A., Reed N.S., Crawford S.M., MacLean A., Swapp G.A., Sarkar T.K., Kennedy J.H., Symonds R.P.: Randomised study ot two doses of cisplatin with cyclophosphamide in epitelial ovarian cancer. Lancet, 340: 329-333, 1992.
19. Lin F.K., Suggs S., Lin C.H., Browne J.K., Smalling R., Egrie J.C., Chen K.K., Fox G.M., Martin F., Stabinsky Z., Badrawi S.M., Lai P.H., Goldwasser E.: Cloning and expression of the human erythropoietin gene. Proc. Natl. Acad. Sci. USA, 82:7580-7585, 1985.
20. Link H., Boogaerts M.A., Flauser A.A., Slavin S., Reiffers J., Gorin N.C., Carella A.M., Mandelli F., Burdach S., Ferrant A., Linkesch W., Tura S., Bacigalupo A., Schindel F., and Heinrichs H.: A controlled trial of recombinant human erythropoietin after bone marrow transplantation. Blood, 84: 3327-3335, 1994.
21. Ludwig H., Fritz E., Kotzmann H., Hocker P., Gisslinger H., Barnas U.: Erythropoietin treatment of anemia asoociated with miltiple myeloma. New Engl. J. Med., 322: 1693-1699, 1990.
22. Ludwig H., Fritz E., Leitgeb C., Pecherstorfer M., Samonigg H., Schuster J.: Prediction of response to erythropoietin treatment in chronic anemia of cancer; Blood, 84: 1056-1063, 1994.
23. Miyake T., Kung C.K.H., Goldwasser E.: Purification of human erythropoietin. J Bioch Chem, 252: 5558-5564, 1977.
24. Osterborg A., Boogaerts M.A., Cimino R., Essers U., Holowiecki J., Juliusson G., Jager G., Najman A., Peest D.: Recombinant human erytropoietin in trasfusion-dependent anemic patients with multiple myeloma and non-hodgking's lynphoma - a randomized multicenter study. Blood, 87: 2675-2682,1996.
25. Pronzato P., Bertelli G., Vigani A., Vaira F.: A feasibility study of accelerated chemotherapy with cisplatin, epidoxorubicin and cyclophosphamide (PEC) in advanced ovarian cancer. Br. J. Cancer, 73: 1425-1427, 1996.
26. Schreiber S., Howaldt S., Schnoor M., Nikolaus S., Bauditz J., Gasché C., Lochs H., Raedler A.: Recombinant Erythropoietin for the treatment of anemia in inflammatory bowel disease. New Engl. J. Med., 334: 619-623, 1996.
27. Skillings J.R., Sridhar F.G., Wong C., Paddock L.: The frequency of red cell transfusion for anemia in patients receiving chemotherapy. A retrospective cohort study. Am. J. Clin. Oncol., 16: 22-25, 1993.
28. Tedeschi L., Locatelli C., D'Antona A., Clerici M., Romanelli A., Luporin G.: Evaluation of incidence of cisplatin (CDDP)-anemia developed in three subsets of noplastic patients. Eur. J. Cancer 31A (Suppl. 5): S55 (abstract 250), 1995.
29. Welch H.G., Meehan K.R., and Goodnough L.T.: Prudent strategies for elective red blood cell transfusion. Ann. Int. Med., 116: 393-402, 1992.
30. Wood P.A., Hrushesky W.J.M.: Cis-platin associated anemia: an erythropoietin deficiency syndrome. J. Clin. Invest, 95: